Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma

    Few strategic decisions in pharmaceutical operations carry as much longterm consequence as the choice of what to make and what to buy and few are revisited as rarely Network footprints agreed a decade ago partners selected during a capacity crunch technology transfers completed under launch pressure these choices harden into architecture They stop looking like decisions and start looking like the...

    Assessing the Impact of Tariffs on the Pharmaceutical Industry

    The pharmaceutical industry function as a vital foundation for worldwide healthcare infrastructure because they push medical advancement while supporting medication availability to patients The pharmaceutical industry deals with major operational obstacles when public authorities establish tariffs for both pharmaceutical imports and exports The implementation of tariffs affects how prices shift wh...

    Spleen Cytokines Against Inflammatory Bowel Disease

    Over one hundred years ago at the University of Toronto Frederick Banting Charles Best and James Collip extracted protein insulin from the pancreas that saved the lives of millions of diabetics since then It is possible that the proteins extracted from the spleen can also help people with inflammatory bowel disease IBD

    Digital Twins in Pharma: What They Are and Why They Matter

    In the current fastpaced life sciences industry Digital Twins Pharma innovations are transforming the industrys conceptualization design testing and delivery of therapeutic products Since intelligent connected and datadriven operations have taken the center stage in pharma companies moving towards the digital age the emergence of Digital Twin Technology in Pharmaceutical structures has been a focu...

    The Growing Role of Real-World Evidence in European Drug Development

    For decades the randomised controlled trial has been the gold standard of pharmaceutical evidence in Europe and it still is Yet the evidence that shapes a medicines journey from laboratory to patient is no longer confined to the controlled world of the trial protocol Electronic health records disease registries insurance claims biobanks and patientreported data are now being mobilised at continent...

    Navigating European Pharma Regulations: A B2B Perspective

    The pharmaceutical industry in the European region practices one of the most regulating laws in the entire world Therefore regulations encompassing these areas are of prime importance for BB companies that need to achieve market entry and maintain compliance Thus this guide is meant to decompartmentalize the array of European pharma regulations and create

TOP ARTICLES

  • 2

    Spleen Cytokines Against Inflammatory Bowel Disease

    Vladimir N Pak

    Spleen cytokines regulate the immune responses through multiple pathways, contributing to a normal function of the immune system. They have been successfully used to treat and heal stomach ulcers in b...

press releases Read more...

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome

Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026

Sapreme Therapeutics a biotechnology company developing nextgeneration RNA therapeutics for patients with genetically driven diseases today announces the oral presentation of new preclinical data from its lead Duchenne muscular dystrophy DMD programme SPM at the nd Annual Meeting of the Oligonucleot...

Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis

Oorja Bio Inc a clinicalstage biopharmaceutical company developing groundbreaking therapies for fibrotic and cardiopulmonary diseases today announced that the first patient has been screened in its ORBITIPF Phase clinical trial evaluating ORJ for the treatment of idiopathic pulmonary fibrosis

Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise

Tenvie Therapeutics a clinicalstage biotechnology company developing precisionengineered small molecule therapies to transform the treatment of neurological and peripheral diseases today announced the first subject dosed in a Phase clinical study evaluating TNV a fully CNSpenetrant small molecule i...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize

Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial

Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics

Enodia Therapeutics announces research and licensing collaboration agreement with Pfizer to develop small molecules directed against Sec61

Enodia Therapeutics a biotech company specializing in the development of innovative therapies with small molecules for the selective degradation of proteins at the point of synthesis today announced the signing of a collaborative research and licensing agreement with Pfizer

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief

Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia

Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...